Acute calcium disorders

Chapter 54 Acute calcium disorders



Calcium is an important cation and the principal electrolyte of the body. A total of 1–2 kg is present in the average adult, of which 99% is found in bone. Of the remaining 1%, nine-tenths is present in the cells and only a tenth in the extracellular fluid. In plasma, 50% of the calcium is ionised, 40% bound to plasma proteins, mainly to albumin, and the remaining 10% is chelated to anions such as citrate, bicarbonate, lactate, sulphate phosphate and ketones.1 The chelated fraction is usually of little clinical importance, but is increased in conditions where some of these anionic concentrations might be elevated, as in renal failure. Whilst most calcium inside the cell is in the form of insoluble complexes, the concentration of intracellular ionised calcium is about 0.1 μmol/l, creating a gradient of 10 000:1 between plasma and intracellular fluid levels of ionised calcium.2 A schematic illustration of calcium distribution within the various body compartments is shown in Figure 54.1.



Because ionised calcium is the biologically active component of extracellular fluid calcium with respect to physiological functions (Table 54.1) and is also the reference variable for endocrine regulation of calcium homeostasis, its measurement is recognised as being one of prime importance in the management of disorders of calcium homeostasis.


Table 54.1 Functions of calcium1,15























Excitation – contraction coupling in cardiac, skeletal and smooth muscle
Cardiac action potentials and pacemaker activity
Release of neurotransmitters
Coagulation of blood
Bone formation and metabolism
Hormone release
Ciliary motility
Catecholamine responsiveness at the receptor site7
Role as a strong cation
Regulation of cell growth and apoptosis


HORMONAL REGULATION OF CALCIUM HOMEOSTASIS1,3


The concentration of ionised calcium in the plasma is subject to tight hormonal control, particularly parathyroid hormone (PTH). A G-protein-coupled calcium receptor plays a significant role in the maintenance of calcium homeostasis. This receptor, responsible for sensing extracellular calcium concentration, is present on the cell membrane of the chief cells of the parathyroid and in bone, gut and the kidney. In response to ionised hypocalcaemia, PTH secretion is stimulated, which in turns serves to restore serum calcium levels back to normal by increasing osteoclastic activity in the bone and renal reabsorption of calcium and stimulating renal synthesis of 1,25 OH-D3 (calcitriol – the active metabolite of vitamin D), which increases gut absorption of calcium.


Calcitriol production is stimulated by hypocalcaemia, and vice versa. Calcitriol increases serum calcium by largely promoting gut reabsorption, and to a lesser extent renal reabsorption of calcium.


Calcitonin, a hypocalcaemic peptide hormone produced by the thyroid, acts as a physiological antagonist to PTH. Although calcitonin has been shown to reduce serum calcium levels in animals by increasing renal clearance of calcium and inhibiting bone resorption, its role in humans is less clear. Despite extreme variations in calcitonin levels, for example total lack in patients who have undergone total thyroidectomy, or excess plasma levels as seen in patients with medullary carcinoma of the thyroid gland, no significant changes in calcium and phosphate metabolism are seen. Calcitonin is useful as a pharmacological agent in the management of hypercalcaemia.



METABOLIC FACTORS INFLUENCING CALCIUM HOMEOSTASIS


Alterations in serum protein, pH, serum phosphate and magnesium closely impact on serum calcium concentrations. Total plasma calcium levels vary with alterations in plasma protein concentration. A correction is made for hypoalbuminaemia by adding 0.2 mmol/l to the measured serum calcium concentration for every 10 g/l decrease in serum albumin concentration below normal (40 g/l). The corresponding correction factor for globulins is –0.04 mmol/l of serum calcium for every 10 g/l rise in serum globulin.


Changes in pH alter calcium protein binding. An increase in pH by 0.1 pH units results in a decrease in ionised calcium by approximately 0.1 mmol/l.4


Calcium and phosphate are closely linked by the following reaction in the extracellular fluid: HPO42− + Ca2+ = CaHPO4. Increases in serum phosphate shift the reaction to the right. When the calcium phosphate solubility product exceeds the critical value of 5 mmol/l, calcium deposition occurs in the tissues, resulting in a fall in serum calcium concentration and a secondary increase in PTH secretion. Reductions in phosphate concentration lead to corresponding changes in the opposite direction.


As magnesium is required for PTH secretion and end-organ responsiveness, alterations in serum magnesium have an impact on serum calcium concentration.


Turnover of calcium in the bone is predominantly under the control of PTH and calcitriol, although prostaglandins and some of the cytokines also play a role in it. Bone resorption is mediated by osteoclasts, whereas osteoblasts are involved in bone formation. The daily calcium balance is summarised in Table 54.2.


Table 54.2 Daily calcium balance






























Gastrointestinal tract
Diet 600–1200 mg/day
Absorbed 200–400 mg/day
Secreted 150–800 mg/day
Renal
Filtered 11 000 mg/day
Reabsorbed (97% in the proximal convoluted tubule) 10 800 mg/day
Urinary calcium 200 mg/day
Bone
Turnover 600–800 mg/day


MEASUREMENT OF SERUM CALCIUM


Most hospital laboratories measure total serum calcium. The normal plasma concentration is 2.2–2.6 mmol/l. However, the ionised form (1.1–1.3 mmol/l) is the active fraction and its measurement is not routine in many laboratories, although most state-of-the-art blood gas analysers can measure serum ionised calcium concentrations. Estimation of ionised calcium from total serum calcium concentration using mathematical algorithms is unreliable in critically ill patients.57 Heparin forms complexes with calcium and decreases ionised calcium.8 A heparin concentration of < 15 units/ml of whole blood is therefore recommended for the measurement of ionised calcium.9 Anaerobic collection of the specimen is recommended, as CO2 loss from the specimen may result in alkalosis and reduction in ionised calcium concentration. Calcium levels are also reduced by a concomitant lactic acidosis owing to chelation by lactate ion.10 Free fatty acids (FFAs) increase calcium binding to albumin and may form a portion of the calcium-binding site.11 Increases in FFAs may be seen in relation to stress, use of steroids, catecholamines and heparin. The impact of pH on calcium measurements has been described above. The normal reference levels of serum calcium are reduced in pregnancy and in the early neonatal period.12



HYPERCALCAEMIA IN CRITICALLY ILL PATIENTS


The frequency of hypercalcaemia in critically ill patients is not well established, although it is not as common as hypocalcaemia. Depending on the patient population, the reported incidence ranges from 3–5% to as high as 32%.13,14 Admission to the intensive care unit (ICU) with a primary diagnosis of a hypercalcaemic crisis is uncommon. Although a number of aetiologies has been described (Table 54.3), in the critical care setting it is usually due to malignancy-related hypercalcaemia, renal failure or posthypocalcaemic hypercalcaemia.15 Before undertaking a work-up for hypercalcaemia, it is important to exclude false-positive measurements. This is usually the result of inadvertent haemoconcentration during venepuncture and elevation in serum protein, although ionised calcium levels are not reported to be affected by haemoconcentration.16Pseudohypercalcaemia has also been described in the setting of essential thrombocythaemia. The erroneous result is thought to be due to in vitro release of calcium from platelets, analogous to the pseudohyperkalaemia seen in the same condition.17


Table 54.3 Causes of hypercalcaemia





















































Common causes of hypercalcaemia in the critically ill patient
Complication of malignancy
Bony metastases
Humoral hypercalcaemia of malignancy
Posthypocalcaemic hypercalcaemia
Recovery from pancreatitis15
Recovery from acute renal failure following rhabdomyolysis3741
Primary hyperparathyroidism
Adrenal insufficiency23,24
Prolonged immobilisation1821
Disorders of magnesium metabolism
Use of total parenteral nutrition42
Hypovolaemia
Iatrogenic calcium administration
Less common causes of hypercalcaemia in the critically ill patient
Granulomatous diseases – sarcoidosis, tuberculosis, berylliosis
Vitamin A and D intoxication
Multiple myeloma
Endocrine
Thyrotoxicosis
Acromegaly
Phaeochromocytoma
Lithium – chronic therapy
Rare association between drugs and hypercalcaemia
Theophylline, omeprazole and growth hormone therapy

From a pathophysiological standpoint, hypercalcaemia may be due to an elevation in PTH, in which case the homeostatic regulatory and feedback mechanisms are preserved, and this is termed equilibrium hypercalcaemia. Alternatively, it could be a non-parathyroid-mediated hypercalcaemia with associated breakdown of homeostatic mechanisms, and this situation is termed dysequilibrium hypercalcaemia.



MECHANISMS OF HYPERCALCAEMIA


Malignancy-related hypercalcaemia might arise from bony metastases or humoral hypercalcaemia of malignancy. In the latter (seen with bronchogenic carcinoma and hypernephroma), tumour osteolysis of bone resulting from the release of PTH-like substances (these cross-react with PTH in the radioimmunoassay, but are not identical to PTH), calcitriol, osteoclast-activating factor and prostaglandins is thought to be the major underlying mechanism. Aggravating factors include dehydration, immobilisation and renal failure.


Posthypocalcaemic hypercalcaemia is a transient phenomenon seen in patients following a period of hypocalcaemia.15 This has been attributed to a parathyroid hyperplasia which develops during the period of hypocalcaemia, resulting in a rebound hypercalcaemia following resolution of the underlying hypocalcaemic disorder.


Immobilisation hypercalcaemia results from an alteration in balance between bone formation and resorption.1821 This leads to loss of bone minerals, hypercalcaemia, hypercalciuria and increased risk of renal failure. In patients with normal bone turnover, immobilisation rarely causes significant hypercalcaemia. However, in patients with rapid turnover of bone (children, postfracture patients, hyperparathyroidism, Paget’s disease, spinal injuries and Guillain–Barré syndrome), this may result in severe hypercalcaemia.


Intravascular volume depletion reduces renal calcium excretion by a combination of reduced glomerular filtration and increased tubular reabsorption of calcium. Hypercalcaemia further compounds this problem by causing a concentrating defect in the renal tubules, thus creating a polyuria and further aggravating the hypovolaemia.


Extrarenal production of calcitriol by lymphocytes in granulomata is thought to be the predominant mechanism of hypercalcaemia in granulomatous diseases.22


Only 10–20% of patients with adrenal insufficiency develop hypercalcaemia.23,24 The aetiology of this is thought to be multifactorial: intravascular volume depletion, haemoconcentration of plasma proteins and the loss of antivitamin D effects of glucocorticoids.


For rarer causes of hypercalcaemia, the reader is referred to a recent review.25

< div class='tao-gold-member'>

Only gold members can continue reading. Log In or Register to continue

Jul 7, 2016 | Posted by in CRITICAL CARE | Comments Off on Acute calcium disorders

Full access? Get Clinical Tree

Get Clinical Tree app for offline access